KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Relacorilant in recurrent ovarian cancer: clinical evidence and future perspectives.

Elena Giudice, Vanda Salutari, Carolina Maria Sassu, Viola Ghizzoni, Maria Vittoria Carbone, Laura Vertechy, Anna Fagotti, Giovanni Scambia, Claudia Marchetti

Expert Rev Anticancer Ther 24(8) 649-655

PMID38861580
PMCID-
DOI10.1080/14737140.2024.2362178
发表日期2024-06-11
摘要

摘要

INTRODUCTION: Relacorilant (CORT125134, Corcept Therapeutics) is a selective glucocorticoid receptor modulator, which reverses the glucocorticoid-mediated anti-apoptotic effects and restores the taxane chemosensitivity in epithelial ovarian cancer cells. Given those preclinical findings, relacorilant is currently under investigation in clinical trials in combination with nab-paclitaxel for the platinum-resistant ovarian cancer setting. AREAS COVERED: Already published preclinical and clinical evidence of relacorilant antitumor activity was analyzed and discussed. Ongoing clinical trials registered on clincaltrials.gov were also reported. The review aimed to summarize the status of relacorilant, the mechanism of action, the published and ongoing trials, and its safety and efficacy. EXPERT OPINION: Relacorilant combined with nab-paclitaxel, may represent a promising strategy for the treatment of platinum-resistant ovarian cancer patients. After preliminary positive results in terms of clinical efficacy, a randomized phase III trial is ongoing to confirm the findings from the published phase II study.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。